Previous Close | 352.20 |
Open | 353.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 342.25 - 353.60 |
52 Week Range | 217.50 - 353.75 |
Volume | |
Avg. Volume | 489,507 |
Market Cap | 414.272B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | 40.63 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.50 (0.14%) |
Ex-Dividend Date | Jul 04, 2024 |
1y Target Est | N/A |
Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023.